COMPASS is the only name that moves materially (±15%) on a catalyst within 10 weeks; peers stay flat absent readouts.

Among all publicly traded psychedelic companies, COMPASS Pathways is the only one likely to see its stock price move sharply — up or down by 15% or more — based on actual clinical trial results in the next ten weeks. Every other company's stock will mostly stay flat because they don't have major data coming out. Real institutional investors (think pension funds and hedge funds) only move money on hard scientific results, not news stories or cultural buzz.

COMPASS is the sole de-risked clinical asset. Cultural noise doesn't move institutional capital — only Phase 3 data does. Everything else is retail chatter.